GSK1360707F
GSK1360707F is a potent and selective triple reuptake inhibitor. It is chemically related to amitifadine and NS-2359 (GSK-372,475). Until recently, it was under development for the treatment of major depressive disorder; its development was put on hold for strategic reasons. Synthesis

BOC Protecting group. Enolization and trapping with triflate group (cf Comins' reagent). Suzuki reaction
Reduction (only 1 mol eq. LAH because N-BOC can be reduced to N-Me)
Trifluoroacetic acid (TFA) removal of protecting group. Simmons–Smith reaction cyclopropanation. Williamson ether synthesis (c.f. NS patents & paxil). Transporter occupancy 
GSK1360707F has recently (2013) been tested on baboons (Papio anubis) & humans for transporter occupancy using PET. See also 
NS-2359

References 

Serotonin–norepinephrine–dopamine reuptake inhibitors